GSK-3β Regulates Tumor Stemness and Immune‐Related Pathways in Triple‐Negative Breast Cancer: A Bioinformatics and Experimental Validation Study
The Breast Journal · 2025
DOI: 10.1155/tbj/5943807 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift The Breast Journal, 2025. Verfasst von Ling Zhou und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thyroid and Breast Surgery, Shanghai Fourth People's Hospital, School of Medicine, Tongji University, Shanghai 200434, China. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Neoplastic Stem Cells, Glycogen Synthase Kinase 3 beta. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
Given the crucial roles of GSK-3β in epithelial–mesenchymal transition (EMT), we assume that it may also be involved in tumor stemness, immune evasion, and drug resistance in triple‐negative breast cancer (TNBC). This study was designed to analyze the expression and clinical significance of GSK-3β and investigate its association with tumor stemness–related and immune‐related genes.
Methods
GSK-3β expression and clinical data of TNBC patients were obtained from TCGA. Survival analysis, differential gene expression, and gene set enrichment analysis (GSEA) were performed to explore associations between GSK-3β and tumor stemness, immune response, and clinical outcomes in TNBC. Immune cell infiltration was assessed using xCell, and key GSK-3β ‐related proteins were validated via parallel reaction monitoring–based proteomics.
Results
GSK-3β expression was significantly upregulated in TNBC and was associated with poorer overall survival. In TNBC, 24 GSK-3β ‐associated genes linked to tumor stemness and immune response were identified, all of which were downregulated in the high GSK-3β expression group. Proteomic analysis further validated differential expression of key proteins, including upregulation of SERPINB2, KIT, and NOTCH1 and downregulation of DNMT1, MAPK1, and EP300 in GSK-3β ‐overexpressing cells.
Conclusion
GSK-3β overexpression was associated with poor prognosis and was found to influence tumor stemness, immune modulation, and key signaling pathways that drive tumor progression and therapeutic resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thyroid and Breast Surgery, Shanghai Fourth People's Hospital, School of Medicine, Tongji University, Shanghai 200434, China.
- Abdominal Surgery Difficult Diagnosis and Treatment Center, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai 200072, China.
Zitieren
APA
Zhou, L., Wang, X., Zhu, H., Chen, Y., Bai, L., Hu, C., Wang, Y., Qi, M., Yin, L., & Sun, J. (2025). GSK-3β Regulates Tumor Stemness and Immune‐Related Pathways in Triple‐Negative Breast Cancer: A Bioinformatics and Experimental Validation Study. The Breast Journal. https://doi.org/10.1155/tbj/5943807
Vancouver
Zhou L, Wang X, Zhu H, Chen Y, Bai L, Hu C, et al. GSK-3β Regulates Tumor Stemness and Immune‐Related Pathways in Triple‐Negative Breast Cancer: A Bioinformatics and Experimental Validation Study. The Breast Journal. 2025. doi:10.1155/tbj/5943807
BibTeX
@article{Zhou2025,
author = {Zhou, Ling and Wang, Xinyu and Zhu, Huiyin and Chen, Yang and Bai, Lifen and Hu, Chunyu and Wang, Yuhan and Qi, Mengfan and Yin, Lu and Sun, Jian},
title = {GSK-3β Regulates Tumor Stemness and Immune‐Related Pathways in Triple‐Negative Breast Cancer: A Bioinformatics and Experimental Validation Study},
journal = {The Breast Journal},
year = {2025},
doi = {10.1155/tbj/5943807}
}
EUVIMED